Nelfinavir Mesylate

For research use only.

Catalog No.S4282 Synonyms: Viracept, AG1343

8 publications

CAS No. 159989-65-8

Nelfinavir Mesylate (Viracept, AG1343) is a potent HIV protease inhibitor with K_i of 2 nM.

Selleck's Nelfinavir Mesylate has been cited by 8 publications

Antimicrob Agents Chemother, 2020, AAC.00872-20

PubMed: 32669265 ( click the link to review the publication )

Antimicrob Agents Chemother, 2020, AAC.01002-20

PubMed: 32601166 ( click the link to review the publication )

Leukemia, 2019, 33(1):37-51

PubMed: 29884901 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3757-3765

PubMed: 31262902 ( click the link to review the publication )

Immunity, 2018, 49(5):842-856

PubMed: 30366764 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):236

PubMed: 30241558 ( click the link to review the publication )

Pharm Res, 2011, 28(2):337-63

PubMed: 20945153 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HIV Protease Inhibitors

Biological Activity

Description

Nelfinavir Mesylate (Viracept, AG1343) is a potent HIV protease inhibitor with K_i of 2 nM.

Targets

HIV protease ^[1]
(Cell-free assay)

2 nM(Ki)

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HeLa	NG\sTppHfW6ldHnvckBie3OjeR?=			NF3hZnZVWF:WUlHOV3BQWlSHUkqgbY5pcWKrdHnvckBw\iCWRVGgeZB1[WunIDjUSWE7KDFyIIXNLUBqdiCRQ2SxMYV5eHKnc4PpcochUGWOYTDj[YxteyxiSVO1NF0zOS56zszNMi=>	NGjKSlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zME[4NVM4QCd-MUC2PFE{Pzh:L3G+
Caco-2	MlTQSpVv[3Srb36gZZN{[Xl?			NW\pNlA6XFChVGLBUnNRV1KWRWK6JIlvcGmkaYTpc44hd2ZiRHH1co9zfWKrY3nuJJRz[W6\|ZYDpeIhmdGmjbDD0doFve3CxcoSgLIJie2GuIITvJIFxcWOjbDmgLGRifW6xcoXibYNqdjpiNTD1UUkhcW5iQ3Hjc{0zKGOnbHzzMEBKSzVyPUGuOO69VS5?	NIThPYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEiyNFE{Pyd-MUC4NlAyOzd:L3G+
MT-4	MoHrRY51cX[rcnHsJIF{e2G7			MmrtRY51cS2KSW[tNUBi[3Srdnn0fUBi\2GrboP0JHdqdGRidInw[UB3cXK3czDpckBOXC12IHPlcIx{NCCHREWwQVAvODMQvF2u	NV7hOIhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG1OFM3PzdpPkGxOVQ{Pjd5PD;hQi=>
MT-4	M3HxTmFvfGm4aYLhcEBie3OjeR?=			MWHBcpRqNUiLVj2xJIFkfGm4aYT5JIFo[Wmwc4SgcZV1[W62IFjJWk0yKGmwIF3UMVQh[2WubIOgLI12fGG2aX;uJJNmdGWldHXkJJdqfGhiY3;tdI92dmRiMTmsJGVFPTB;MD6wO:69VS5?	MkPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF3NEO2O\|coRjFzNUSzOlc4RC:jPh?=
MT-4	NFj3W21CdnSrdnnyZYwh[XO\|YYm=			NIXlUYlCdnSrLVjJWk0yKGGldHn2bZR6KGGpYXnud5QhdXW2YX70JGhKXi1zIHnuJG1VNTRiY3XscJMhMG23dHH0bY9vKHOnbHXjeIVlKHerdHigdol1d26jdnnyLUwhTUR3ME2wMlEy\|ryPLh?=	NWDYXZdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG1OFM3PzdpPkGxOVQ{Pjd5PD;hQi=>
MT-4	MXHBcpRqfmm{YXygZZN{[Xl?			NHTWc4JCdnSrLVjJWk0yKGGldHn2bZR6KGGpYXnud5QhdXW2YX70JGhKXi1zIHnuJG1VNTRiY3XscJMhMG23dHH0bY9vKHOnbHXjeIVlKHerdHigd4FyfWmwYY\pdkktKEWGNUC9NE4yOs7:TT6=	NV21[GlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG1OFM3PzdpPkGxOVQ{Pjd5PD;hQi=>
MT-4	MmLpRY51cX[rcnHsJIF{e2G7			NGXIUldCdnSrLVjJWk0yKGGldHn2bZR6KGGpYXnud5QhdXW2YX70JGhKXi1zIHnuJG1VNTRiY3XscJMhMG23dHH0bY9vKHOnbHXjeIVlKHerdHigcoVt\mmwYY\pdkktKEWGNUC9Nk41PM7:TT6=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTV2M{[3O{c,OTF3NEO2O\|c9N2F-
LLC-PK1	NUXnXZVRTnWwY4Tpc44h[XO\|YYm=			NGPkOVJKdmirYnn0bY9vKG:oIGCt[4x6[2:ycn;0[YlvNCCvb4Xz[UBNNW2mckHhJIV5eHKnc4Pl[EBqdiCOTFOtVGsyKGWyaYTo[Yxq[WxiY3XscJMhfXOrbnegZ4Ft[2Wrbj3BUUBxd2yjcnnzZZRqd25iYYPzZZktKEmFNUC9Nk4{\|ryPLh?=	NX7pTpVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2PVk{QDlpPkGyOlk6Ozh7PD;hQi=>
LLC-PK1	M1P2UmZ2dmO2aX;uJIF{e2G7			NYjSeHVkXFChVGLBUnNRV1KWRWK6JIlvcGmkaYTpc44hd2ZiQ3HsZ4Vqdi2DTTDl[oZtfXhiaX6gUYRzOWFvZYjwdoV{e2mwZzDMUGMuWEtzIHPlcIx{NCCLQ{WwQVIvO87:TT6=	M1zPW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{Nkm5N\|g6Lz5zMk[5PVM5QTxxYU6=
LLC-PK1	NYH1UmJvTnWwY4Tpc44h[XO\|YYm=			NULpOZRjUW6qaXLpeIlwdiCxZjDQMYdtgWOxcILveIVqdixiaIXtZY4hVC2PRGKxJIV5eHKnc4Pl[EBqdiCOTFOtVGsyKGWyaYTo[Yxq[WxiY3XscJMhfXOrbnegZ4Ft[2Wrbj3BUUBxd2yjcnnzZZRqd25iYYPzZZktKEmFNUC9N{41\|ryPLh?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZ7OUO4PUc,OTJ4OUmzPFk9N2F-
LLC-PK1	MkDhSpVv[3Srb36gZZN{[Xl?			M3jUXnRRZ1SUQV7TVG9TXEWUOjDpcohq[mm2aX;uJI9nKEOjbHPlbY4uSU1iZX\mcJV5KGmwIF3EVlEu\XiycnXzd4lv\yCOTFOtVGsyKGOnbHzzMEBKSzVyPUOuOO69VS5?	Mo\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4OUmzPFkoRjF{Nkm5N\|g6RC:jPh?=
HEK	MWjGeY5kfGmxbjDhd5NigQ>?			MUfUVH9VWkGQU2DPVnRGWjpiaX7jdoVie2ViaX6gcYl1d3ijboTyc45mKGmwdILhZ4VtdHWuYYKgZYNkfW23bHH0bY9vKGmwIFLDVnAu\XiycnXzd4lv\yCKRVugZ4VtdHNuIFnDOVA:OTJwNd88UU4>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTByN{GwNkc,OTVyMEexNFI9N2F-
CEM-SS	M17IWGFvfGm4aYLhcEBie3OjeR?=		M3vG[FYh\GG7cx?=	M3PnWGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDh[pRmeiB4IHThfZMh[nliTWTTJIF{e2G7LDDFSFUxRTBwMEROwG0v	NGHBU\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUKxO\|I5OSd-MUWyNVczQDF:L3G+
HOG.R5	M{XZbGFvfGm4aYLhcEBie3OjeR?=		NUfQRopNPCCmYYnz	MUPBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIFjPS{5TPSClZXzsd{Bi\nSncjC0JIRigXNuIFnDOVA:OC5yOd88UU4>	MkPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV{MUeyPFEoRjF3MkG3NlgyRC:jPh?=
MT-4	Ml3RSpVv[3Srb36gZZN{[Xl?			MV;F[oZm[3SrdnWg[I9{\SCxZjDjc41xd3WwZDDy[ZF2cXKnZDD0c{BqdmirYnn0JJJmeGyrY3H0bY9vKG:oIHj1cYFvKGmvbYXuc4Rm\mmlaXXuZ5khfmm{dYOgeJlx\SBzIHnuJG1VNTRiY3XscJMtKEWGNUC9NE4xOs7:TT6=	M1LYWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NUO3N\|UxLz5zNUWzO\|M2ODxxYU6=
MT4	M1Lsc2FvfGm4aYLhcEBie3OjeR?=			M1nEeWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiSGjCNkBqdiCPVESgZ4VtdHNuIFnDOVA:OC5\|Mt88UU4>	MlvvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2NUi1NFUoRjF4NEW4OVA2RC:jPh?=
MT4	MmW0RY51cX[rcnHsJIF{e2G7			M2DDV2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiRWCxN{BqdiCPVESgZ4VtdHNuIFnDOVA:OC52Nd88UU4>	MmjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2NUi1NFUoRjF4NEW4OVA2RC:jPh?=
PHA-PBMC	NVPC[ZpWSW62aY\pdoFtKGG\|c3H5			MWHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEKDLVygbZNwdGG2ZTDpckBpfW2jbjDQTGEuWEKPQzDj[YxteyxiSVO1NF0xNjByN988UU4>	NFf2NlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmxN\|cyPCd-MU[5NVM4OTR:L3G+
MT2	NGTC[4NCdnSrdnnyZYwh[XO\|YYm=			NHLISopCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIFzBTUBqe2:uYYTlJIlvKGi3bXHuJG1VOiClZXzsd{whUUN3ME2wMlAy\|ryPLh?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjlzM{exOEc,OTZ7MUO3NVQ9N2F-
PHA-PBMC	NWHTeGpiSW62aY\pdoFtKGG\|c3H5			MlzVRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCOQVmgbZNwdGG2ZTDpckBpfW2jbjDQTGEuWEKPQzDj[YxteyxiSVO1NF0xNjBzNN88UU4>	NUfkR2lvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NVM4OTRpPkG2PVE{PzF2PD;hQi=>
MT2	NVHobWtHSW62aY\pdoFtKGG\|c3H5			NWrZeoE1SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMjDFTG8hcXOxbHH0[UBqdiCqdX3hckBOXDJiY3XscJMtKEmFNUC9NE4xOs7:TT6=	M1Po[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUGzO\|E1Lz5zNkmxN\|cyPDxxYU6=
PHA-PBMC	NEPJPVhCdnSrdnnyZYwh[XO\|YYm=			M2\UT2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JI12dHSrIHTyeYcuemW\|aYP0ZY51KEiLVkGgSXQhfmG{aXHueEBqdiCqdX3hckBRUEFvUFLNR{Bk\WyuczygTWM2OD1yLkCzNu69VS5?	NUizZlF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NVM4OTRpPkG2PVE{PzF2PD;hQi=>
PHA-PBMC	NF;NR25CdnSrdnnyZYwh[XO\|YYm=			MYLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDteYx1cSCmcoXnMZJme2m\|dHHueEBJUVZzIFegeoFzcWGwdDDpckBpfW2jbjDQTGEuWEKPQzDj[YxteyxiSVO1NF0xNjF5zszNMi=>	NIT0VoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmxN\|cyPCd-MU[5NVM4OTR:L3G+
PHA-PBMC	MYLBcpRqfmm{YXygZZN{[Xl?			MojHRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgcZVtfGliZIL1[{1z\XOrc4ThcpQhUEmYMTDDJJZiemmjboSgbY4hcHWvYX6gVGhCNVCETVOgZ4VtdHNuIFnDOVA:OC5\|Md88UU4>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjlzM{exOEc,OTZ7MUO3NVQ9N2F-
MT2	MWXBcpRqfmm{YXygZZN{[Xl?			NIjmVpdCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZ{IFXIU{BqdiCPVEKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4h\XiycnXzd4lwdiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wN:69VS5?	M3zaTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT2	M4D3XGFvfGm4aYLhcEBie3OjeR?=			MkjpRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCOQVmgbY4hVVR{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDJ2IFfh[{Bxem:2ZXnuJIV5eHKnc4Ppc44h[nliTWTUJIF{e2G7LDDFR\|UxRTBwMEOy{txONg>?	NXPyfpRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezO\|E5OTFpPkG3N\|cyQDFzPD;hQi=>
MT4	MXnBcpRqfmm{YXygZZN{[Xl?			M1zy[2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTly0MVMhcW5iTWS0JINmdGy\|IHL5JG1VXCCjc4PhfUwhTUN3ME2wMlA{O87:TT6=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	M{\aVWFvfGm4aYLhcEBie3OjeR?=			MVzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEeUTEm4NFY2eDJyIHnuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCJYXegdJJwfGWrbjDlfJBz\XO\|aX;uJIJ6KE2WVDDhd5NigSxiRVO1NF0xNjB6zszNMi=>	MmHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|N{G4NVEoRjF5M{exPFEyRC:jPh?=
MT4	MXrBcpRqfmm{YXygZZN{[Xl?			Mn75RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgdol1d26jdnnyMZJme2m\|dHHueEBJUVZzIHnuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCJYXegdJJwfGWrbjDlfJBz\XO\|aX;uJIJ6KE2WVDDhd5NigSxiRVO1NF0xNjJzzszNMi=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	MX;BcpRqfmm{YXygZZN{[Xl?			NV3H[Gg3SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qh[W2ycnXuZZZqei2{ZYPpd5RidnRiSFnWNUBqdiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4h\XiycnXzd4lwdiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6yNu69VS5?	MmjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|N{G4NVEoRjF5M{exPFEyRC:jPh?=
MT2	NFnRVXRCdnSrdnnyZYwh[XO\|YYm=			M1PMZWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjJiUl;EJIlvKE2WMjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBmgHC{ZYPzbY9vKGK7IF3UWEBie3OjeTygSWM2OD1yLkK0{txONg>?	NV;IUFVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezO\|E5OTFpPkG3N\|cyQDFzPD;hQi=>
MT4	M{TYemFvfGm4aYLhcEBie3OjeR?=			NWTDOYRXSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qh[XSjenHuZZZqei2{ZYPpd5RidnRiSFnWNUBqdiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4h\XiycnXzd4lwdiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6yO:69VS5?	NInFb5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O3NVgyOSd-MUezO\|E5OTF:L3G+
MT4	Ml7qRY51cX[rcnHsJIF{e2G7			Mlm5RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCJUly5PFA3PXB\|MDDpckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC5{N988UU4>	MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|N{G4NVEoRjF5M{exPFEyRC:jPh?=
MT4	Ml\CRY51cX[rcnHsJIF{e2G7			NH\ZSmFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIFfSUFk5ODZ3cESwJIlvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBmgHC{ZYPzbY9vKGK7IF3UWEBie3OjeTygSWM2OD1yLkO0{txONg>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	MUXBcpRqfmm{YXygZZN{[Xl?			MV7BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDp[Ilv[X[rcj3y[ZNqe3SjboSgTGlXOSCrbjDNWFQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDwNlQhT2GpIIDyc5RmcW5iZYjwdoV{e2mxbjDifUBOXFRiYYPzZZktKEWFNUC9NE41P87:TT6=	M1fNUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT4	NV\0RpExSW62aY\pdoFtKGG\|c3H5			MnOyRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgd4FyfWmwYY\pdk1z\XOrc4ThcpQhUEmYMTDpckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC52ON88UU4>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	M{DBT2FvfGm4aYLhcEBie3OjeR?=			NX76R2VkSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhdG:yaX7heolzNXKnc3nzeIFvfCCKSW[xJIlvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBmgHC{ZYPzbY9vKGK7IF3UWEBie3OjeTygSWM2OD1yLkS5{txONg>?	M4fENlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT2	Mm\nR5l1d3SxeHnjbZR6KGG\|c3H5			NFPqVZZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXDJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFPDOVA:QC5zzszNMi=>	MkfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|N{G4NVEoRjF5M{exPFEyRC:jPh?=
MT4	NH31fINCdnSrdnnyZYwh[XO\|YYm=			MUHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnuJG1VPCClZXzsd{BjgSCPVGSgZZN{[XluIFXDOVA:OC5yMUdOwG0v	M1;YbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUO3OlI5Lz5zN{WzO\|YzQDxxYU6=
MT4	MoXMR5l1d3SxeHnjbZR6KGG\|c3H5			NX:3fYdCS3m2b4TvfIlkcXS7IHHnZYlve3RiTWS0JINmdGy\|IHL5JG1VXCCjc4PhfUwhVEN3ME2xNe69VS5?	MlzEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3M{e2NlgoRjF5NUO3OlI5RC:jPh?=
MT4	NGm5flJCdnSrdnnyZYwh[XO\|YYm=		NVriXJRHPSCmYYnz	MV7BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKE6OND2zJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCjZoTldkA2KGSjeYOgZpkhVVSWIHHzd4F6NCCHQ{WwQVAvODF6zszNMi=>	M2DKXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUe2PFQ5Lz5zN{W3Olg1QDxxYU6=
MT4	MYHBcpRqfmm{YXygZZN{[Xl?		M2PYUFUh\GG7cx?=	Ml\pRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOiCPUzDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[W[2ZYKgOUBl[Xm\|IHL5JG1VXCCjc4PhfUwhTUN3ME2wMlA1QM7:TT6=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5Nki0PEc,OTd3N{[4OFg9N2F-
CEM	MWTBcpRqfmm{YXygZZN{[Xl?		NFzIUmg4KGSjeYO=	NX;rdVNvSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMjDSU2Qhf2m2aDDwdo91\WG\|ZTDHNVdPN1Z2N1GgcZV1[XSrb36gbY5n\WO2ZXSgbY4hcHWvYX6gR2VOKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNicILv[JVkfGmxbjDh[pRmeiB5IHThfZMh[nliTHXueIkuWlRiYXP0bZZqfHliYYPzZZktKEWFNUC9NE4y\|ryPLh?=	NWD6Rmc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1O\|Y5PDhpPkG3OVc3QDR6PD;hQi=>
CEM	NUjGN3VNSW62aY\pdoFtKGG\|c3H5		NEf4RZU4KGSjeYO=	M2Tnd2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjJiUl;EJJdqfGhicILveIVie2ViVkS3RUBufXSjdHnvckBqdm[nY4Tl[EBqdiCqdX3hckBETU1iY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3czDwdo9lfWO2aX;uJIFnfGW{IEeg[IF6eyCkeTDM[Y51cS2UVDDhZ5Rqfmm2eTDhd5NigSxiRVO1NF0xNjF5N988UU4>	NVe1WJZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1O\|Y5PDhpPkG3OVc3QDR6PD;hQi=>
CEM	MoLhRY51cX[rcnHsJIF{e2G7		MYG3JIRigXN?	Mnj0RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOiCUT1Sge4l1cCCycn;0[YF{\SCJMUfOJI12fGG2aX;uJIlv\mWldHXkJIlvKGi3bXHuJGNGVSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|IIDyc4R2[3Srb36gZYZ1\XJiNzDkZZl{KGK7IFzlcpRqNVKWIHHjeIl3cXS7IHHzd4F6NCCHQ{WwQVAvOTl7zszNMi=>	NVjZUmtiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1O\|Y5PDhpPkG3OVc3QDR6PD;hQi=>
CEM	NUPhVYhbSW62aY\pdoFtKGG\|c3H5		NIrheJk4KGSjeYO=	NU\tSWtlSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEiLVkKgVm9FKGmwZnXjeIVlKGmwIHj1cYFvKEOHTTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzJJBzd2S3Y4Tpc44h[W[2ZYKgO{Bl[Xm\|IHL5JGxmdnSrLWLUJIFkfGm4aYT5JIF{e2G7LDDFR\|UxRTBwMkix{txONg>?	Mn\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3N{[4OFgoRjF5NUe2PFQ5RC:jPh?=
HEK293	MWDBcpRqfmm{YXygZZN{[Xl?		NEH6Snk1QCCqcoO=	MorsRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFiTly0MVMhcW5iSFXLNlk{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDy[ZBtcWOjdHnvck1l\W[oZXP0bZZmKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[U1j[XOnZDDwbIVvd3S7cHnjJIF{e2G7LDDFR\|UxRTBwMEC1PO69VS5?	MkPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4M{i2PVQoRjF5NkO4Olk1RC:jPh?=
MT4	M321Z2FvfGm4aYLhcEBie3OjeR?=		NV;LOIR[PiCmYYnz	NFGyNXhCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhUEmYMTDOUFQuOyCrbn\lZ5Rm\CCrbjDNWFQh[2WubIOgZYZ1\XJiNjDkZZl{KGK7IF3UWEBie3OjeTygSWM2OD1yLkCyPe69VS5?	NXi2dGExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2N\|g3QTRpPkG3OlM5Pjl2PD;hQi=>
MT4	M3TmPGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MYW2JIRigXN?	MmK3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzJIFnfGW{IE[g[IF6eyCkeTDNWHQh[XO\|YYmsJGNEPTB;ON88UU4>	NVe0ZoxSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2N\|g3QTRpPkG3OlM5Pjl2PD;hQi=>
HEK293	NX3YSIFUTnWwY4Tpc44h[XO\|YYm=	MUWwMlEzKHWP		M33YXWlvcGmkaYTpc44hd2ZiSFnWNUBPVDRvMzDwdo91\WmwczDpcoNwenCxcnH0bY9vKGmwdH:geolzcW:wczD0doFve2[nY4Tl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMhfW6ycn;j[ZN{\WRiZ4CxOlAhTW64IIDyc5RmcW5iYYSgNE4yOiC3TTDifUBY\XO2ZYLuJIJtd3R?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ2NkSxNEc,OTd4NE[0NVA9N2F-
HEK293	NGS2RVFHfW6ldHnvckBie3OjeR?=	NIHXc48xNjF{IIXN		M{Pz[mlvcGmkaYTpc44hd2ZiSFnWNUBPVDRvMzDwdo91\WmwczDpcoNwenCxcnH0bY9vKGmwdH:geolzcW:wczD0doFve2[nY4Tl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMh[WKncoLhcpQhTW64IIDyc5RmcW5iYYSgNE4yOiC3TTDifUBY\XO2ZYLuJIJtd3R?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ2NkSxNEc,OTd4NE[0NVA9N2F-
MDCK2	Mlr4TY5pcWKrdHnvckBw\iCqdX3hci=>			MYjJcohq[mm2aX;uJI9nKGi3bXHuJG1FWjFvZHXw[Y5l\W62IHHjZ5VufWyjdHnvckBw\iClYXzj[YlvNUGPIHX4dJJme3OnZDDpckBOTEONMjDj[YxteyxiSVO1NF0yQS57zszNMi=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ4NEOyO{c,OTd4NkSzNlc9N2F-
MDR1	Mn\hSpVv[3Srb36gZZN{[Xl?	NXXkNVhTOjBidV2=		NGPlOolF\WO{ZXHz[UBqdiCSLXfsfYNweHKxdHXpck1u\WSrYYTl[EB1\W6xZn;2bZIh\Gm\|b4Dyc5hqdCCodX3hdoF1\SCnZn\seZghcW5iTVTDT\|Ih\XiycnXzd4lv\yCqdX3hckBOTFJzIHPlcIx{KGG2IEKwJJVO	NYfxS3R2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2OlQ{OjdpPkG3OlY1OzJ5PD;hQi=>
CEM-SS	MkSxRY51cX[rcnHsJIF{e2G7		NH7TWnU2KGSjeYO=	MnHHRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCOQVmgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGG\|c3Xzd4VlKGG\|IILleoVze2VidILhcpNkemmydHHz[UBi[3Srdnn0fUBi\nSncjC1JIRigXNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNFAz\|ryPLh?=	NVvHW3MxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OVA6PTVpPkG3PVUxQTV3PD;hQi=>
MOLT-4/3B	MkLvRY51cX[rcnHsJIF{e2G7		MWW0JIRigXN?	NE[2WoFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIEPCJIlv\mWldHXkJIlvKE2RTGStOE8{SiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJI1ifHW{ZTD2bZJ2eyC{ZXzlZZNmKG2nYYP1doVlKGGodHXyJFQh\GG7czDv[kBqdm[nY4Tpc44h[nliUmSgZZN{[XluIFXDOVA:OC5yMkpOwG0v	NITjdnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxOlUzOSd-MUizNVY2OjF:L3G+
MT4	MYHBcpRqfmm{YXygZZN{[Xl?			NVHsPFBySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbD3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCvZYToc4QtKEWFNUC9NE4xOTcQvF2u	NI\2[Xk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESyOlE6PSd-MUi0NlYyQTV:L3G+
MT4	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=			M1\pe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1VPCClZXzsd{BjgSCPVGSgZZN{[XluIFPDOVA:OTIQvF2u	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR{NkG5OUc,OTh2Mk[xPVU9N2F-
MT4	MWnBcpRqemW2cn;2bZJidCCjc4PhfS=>			NHXXN5VCdnSrcnX0do93cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFj1cYFvKGmvbYXuc4Rm\mmlaXXuZ5khfmm{dYOgNUBPVDRwMzDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGK7IF3UWEBie3OjeTygSWM2OD1yLkCyN:69VS5?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV2MUeyOkc,OTh3NEG3NlY9N2F-
MT4	MWDBcpRqemW2cn;2bZJidCCjc4PhfS=>			NWH6THpLSW62aYLleJJwfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBjgSCPVGSgZZN{[XluIFXDOVA:OC5yMklOwG0v	Moj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	MoHHRY51cX[rcnHsJIF{e2G7			NYDne2I4SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHnubIljcXSxcj3y[ZNqe3SjboSgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZpkhVVSWIHHzd4F6NCCHQ{WwQVAvODJ7zszNMi=>	Mm\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	MX3BcpRqfmm{YXygZZN{[Xl?			MVHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDuc44hdnWlbHXvd4ll\SC{ZY\ldpNmKHS{YX7zZ5JqeHSjc3WgbY5pcWKrdH;yMZJme2m\|dHHueEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBjgSCPVGSgZZN{[XluIFXDOVA:OC5yM{ZOwG0v	M2e1NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUSxO\|I3Lz5zOEW0NVczPjxxYU6=
MT4	NFrFZmRCdnSrcnX0do93cXKjbDDhd5NigQ>?			MmfWRY51cXKndILveolz[WxiYXP0bZZqfHliYXfhbY5{fCCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW\|IEKgSWhQKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZpkhVVSWIHHzd4F6NCCHQ{WwQVAvODR7zszNMi=>	NVvCO5pjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OFE4OjZpPkG4OVQyPzJ4PD;hQi=>
MT4	NHrWcWdCdnSrcnX0do93cXKjbDDhd5NigQ>?			MW\BcpRqemW2cn;2bZJidCCjY4Tpeol1gSCjZ3HpcpN1KEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMjDSU2QhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDifUBOXFRiYYPzZZktKEWFNUC9NE4xPc7:TT6=	NH3hc\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW0NVczPid-MUi1OFE4OjZ:L3G+
MT4	MWXBcpRqemW2cn;2bZJidCCjc4PhfS=>			M1PVS2FvfGm{ZYTyc5ZqemGuIHHjeIl3cXS7IHHnZYlve3RiU3ntbYFvKGmvbYXuc4Rm\mmlaXXuZ5khfmm{dYOgUWFEKDJ3MTDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGK7IF3UWEBie3OjeTygSWM2OD1yLkC1{txONg>?	NFe3T2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW0NVczPid-MUi1OFE4OjZ:L3G+
MT4	M3TRTGFvfGm4aYLhcEBie3OjeR?=			M1vXXWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHBzd3SnYYPlJIlvcGmkaYTvdk1z\XOrc4ThcpQhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7LDDFR\|UxRTBwMUhOwG0v	MlnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	M1PXWWFvfGm4aYLhcEBie3OjeR?=	NVqwSVF4PSC3TR?=		MmXxRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochVDFyRj;MN\|NHN012NlmvTVQ4Xi:TNUjFM3Y5OklxSUi0Wk9KQDWYIHHtbY5wKGGlaXSgd5Vje3SrdIX0bY9vKGmwIIDyc5Rm[XOnIHXuZ49lcW6pIILl[4lwdiCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4heHKxZIXjeIlwdiC\|ZXzlZ5Rm\CCjdDC1JJVOKG:oIFfSUE0xOjB\|MTDifUBGNCCHQ{WwQVAvODFzzszNMi=>	M2fWSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUW1OVE5Lz5zOEm1OVUyQDxxYU6=
MT4	MYPBcpRqfmm{YXygZZN{[Xl?			MWjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKE6OND2zJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCpYXegdJJwfGWrbjDwdo9lfWO2aX;uJIJ6KEWOSWPBMEBGSzVyPUCuNFE5\|ryPLh?=	NFv1XHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm1OVUyQCd-MUi5OVU2OTh:L3G+
MT2	M1P0WWFvfGm4aYLhcEBie3OjeR?=		MnPDO{Bl[Xm\|	NF3zeGJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIFzBTUBqdm[nY4Tl[EBqdiCqdX3hckBOXDJiY3XscJMh[W[2ZYKgO{Bl[Xm\|IHL5JG1VXCCjc4PhfUwhTUN3ME2wMlAzO87:TT6=	M4K1O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUW1OVE5Lz5zOEm1OVUyQDxxYU6=
MT4	NYTF[lhSSW62aY\pdoFtKGG\|c3H5	MWi1JJVO		MV\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKE6OND2zJIhiemKxcnnu[{BNOTCIL2[zNmkwVTR4ST;JOVRONy:DN{HWM2k5PFZiYX3pco8h[WOrZDDzeYJ{fGm2dYTpc44hcW5icILveIVie2ViZX7jc4RqdmdicnXnbY9vKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBxem:mdXP0bY9vKHOnbHXjeIVlKGG2IEWgeW0hd2ZiYX3wdoVv[X[rcjDifUBGVEmVQTygSWM2OD1yLkG3{txONg>?	M3HGZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUW1OVE5Lz5zOEm1OVUyQDxxYU6=
MT4	M1XScWFvfGm4aYLhcEBie3OjeR?=	NYnPNoJMOSC3TR?=		MWDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKE6OND2zJIhiemKxcnnu[{BNOjOLL1u0N2kwVTR4ST;JOVBNN0d3MVGvRVcyXiCjbXnuc{Bi[2mmIIP1ZpN1cXS3dHnvckBqdiCycn;0[YF{\SCnbnPv[Ilv\yC{ZXfpc44hcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDJ2IFfh[{Bxem:2ZXnuJJBzd2S3Y4Tpc44he2WuZXP0[YQh[XRiMTD1UUBw\iCjdHH6ZY5ifmm{IHL5JGVNUVODLDDFR\|UxRTBwMkJOwG0v	M3\EflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUW1OVE5Lz5zOEm1OVUyQDxxYU6=
MT4	MYTBcpRqfmm{YXygZZN{[Xl?	NUPUdZQ2PSC3TR?=		NWPH[FRSSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQuOyCqYYLic5JqdmdiTUS2TU9XQDKIL1m4OHYh[W2rbn:gZYNq\CC\|dXLzeIl1fXSrb36gbY4heHKxdHXhd4Uh\W6lb3TpcochemWpaX;uJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCJYXegdJJwfGWrbjDwdo9lfWO2aX;uJJNmdGWldHXkJIF1KDVidV2gc4Yhemm2b37heolzKGK7IFXMTXNCNCCHQ{WwQVAvOjUQvF2u	Mlj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7NUW1NVgoRjF6OUW1OVE5RC:jPh?=
MT4	M{TDcWFvfGm4aYLhcEBie3OjeR?=	MWm1JJVO		NEPaVoJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIF7MOE0{KGijcnLvdolv\yCOMUDJM2c1QFZxSUW0Wk9NQTCPIHHtbY5wKGGlaXSgd5Vje3SrdIX0bY9vKGmwIIDyc5Rm[XOnIHXuZ49lcW6pIILl[4lwdiCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4heHKxZIXjeIlwdiC\|ZXzlZ5Rm\CCjdDC1JJVOKG:oIIPhdZVqdmG4aYKgZpkhTUyLU1GsJGVEPTB;MD6zNu69VS5?	Mn;4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7NUW1NVgoRjF6OUW1OVE5RC:jPh?=
MT4	MlXTRY51cX[rcnHsJIF{e2G7	MnTyNUB2VQ>?		MnXWRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochVDFyRj;NOFZKN0l3NG[vWlgzSSCjbXnuc{Bi[2mmIIP1ZpN1cXS3dHnvckBqdiCycn;0[YF{\SCnbnPv[Ilv\yC{ZXfpc44hcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDJ2IFfh[{Bxem:2ZXnuJJBzd2S3Y4Tpc44he2WuZXP0[YQh[XRiMTD1UUBw\iCOb4DpcoF3cXJiYomgSWxKW0FuIFXDOVA:OC53Md88UU4>	MkLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7NUW1NVgoRjF6OUW1OVE5RC:jPh?=
MT4	M1vRXGFvfGm4aYLhcEBie3OjeR?=	NG\ENYo2KHWP		M2DuO2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTly0MVMhcGG{Yn;ybY5oKExzMF[vUFI1US:PNE\JM2w3O1BxQUexWk9IPzOVL2[4NnQh[W2rbn:gZYNq\CC\|dXLzeIl1fXSrb36gbY4heHKxdHXhd4Uh\W6lb3TpcochemWpaX;uJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCJYXegdJJwfGWrbjDwdo9lfWO2aX;uJJNmdGWldHXkJIF1KDVidV2gc4YhcW6maX7heolzKGK7IFXMTXNCNCCHQ{WwQVAvPjYQvF2u	NULnTJBERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5OVU2OThpPkG4PVU2PTF6PD;hQi=>
HeLa	MXvBcpRqfmm{YXygZZN{[Xl?		NHj5Ums4OiCqcoO=	MWDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGijcnLvdolv\yClYYDzbYQhUTJyMW[gcZV1[W62IIDyc5RmcW5iaX7m[YN1\WRiaX6gbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC4aYLhcEBqdm[nY4Tpc44h[W[2ZYKgO\|IhcHK\|IHL5JIJmfGFvZ3HsZYN1d3OrZHHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODF\|zszNMi=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQThyNUW3NUc,OTl6MEW1O\|E9N2F-
HeLa	MVrBcpRqfmm{YXygZZN{[Xl?		M4TMT\|czKGi{cx?=	MXnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgTGlXOSCrbn\lZ5Rm\CCrbjDoeY1idiCKZVzhJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKH[rcnHsJIlv\mWldHnvckBi\nSncjC3NkBpenNiYomgZoV1[S2pYXzhZ5Rwe2mmYYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xOTcQvF2u	NH\nXog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiwOVU4OSd-MUm4NFU2PzF:L3G+
HeLa	M2r3bmFvfGm4aYLhcEBie3OjeR?=		NIPsW2I4OiCqcoO=	M3jQVGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaHHyZo9zcW6pIIPwZYNmeiCyZYD0bYRmKEFzVjDteZRidnRicILveIVqdiCrbn\lZ5Rm\CCrbjDoeY1idiCKZVzhJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKH[rcnHsJIlv\mWldHnvckBi\nSncjC3NkBpenNiYomgZoV1[S2pYXzhZ5Rwe2mmYYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xOzkQvF2u	NFnzfWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiwOVU4OSd-MUm4NFU2PzF:L3G+
cord blood mononuclear cells	MoH3RY51cX[rcnHsJIF{e2G7		NV7MdFFnPDhiaILz	MoL4RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFic4XieJlx\SCFIHnu[oVkfGWmIHnuJIh2dWGwIHPvdoQh[myxb3SgcY9vd263Y3zlZZIh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjDh[pRmeiB2ODDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyPUCuNFAyPjgQvF2u	M{WwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEC0NVI{Lz5{MESwOFEzOzxxYU6=
cord blood mononuclear cells	NHvLfpBCdnSrdnnyZYwh[XO\|YYm=		NGCzXGk1QCCqcoO=	NHG0fmxCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhUEmYMTDzeYJ1gXCnIFPSSlAzZ0GJIHnu[oVkfGWmIHnuJIh2dWGwIHPvdoQh[myxb3SgcY9vd263Y3zlZZIh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjDh[pRmeiB2ODDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyPUCuNFA2P87:TT6=	NGrocZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOFEzOyd-MkC0NFQyOjN:L3G+
cord blood mononuclear cells	NXfMZYV[SW62aY\pdoFtKGG\|c3H5		M3G2dVQ5KGi{cx?=	M3m1e2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJdqdGRidInw[UBJUVZzIIP1ZpR6eGViQjDpcoZm[3SnZDDpckBpfW2jbjDjc5JlKGKub3;kJI1wdm:wdXPs[YFzKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlAxQTkQvF2u	M1\0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEC0NVI{Lz5{MESwOFEzOzxxYU6=
cord blood mononuclear cells	MYLBcpRqfmm{YXygZZN{[Xl?		MoL5OFghcHK\|	NFvteYhCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIIP1ZpR6eGViQ2LGNFJgSUdiaHHyZo9zcW6pIIDyc5Rm[XOnIIDvcJlud3KyaHnzcUBifCCLM{[gdI9{cXSrb36gZY5lKE12NjDteZRidnRiZ3Xu[UBqdm[nY4Tl[EBqdiCqdX3hckBkd3KmIHLsc49lKG2xbn;ueYNt\WG{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjB3Nd88UU4>	NW\adYZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
cord blood mononuclear cells	NUToWmFISW62aY\pdoFtKGG\|c3H5		M2HSSlQ5KGi{cx?=	NFj6fGxCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIIP1ZpR6eGViQ2LGNFJgSUdiaHHyZo9zcW6pIIDyc5Rm[XOnIFyzN2ktKE12NlmsJGE4OVRibYX0ZY51KGenbnWgZY5lKHCxbIntc5JxcGm\|bTDheEBOOzZicH;zbZRqd25iaX7m[YN1\WRiaX6gbJVu[W5iY3;y[EBjdG:xZDDtc45wdnWlbHXhdkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKHKncHzpZ4F1cW:wIHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGVuIFXDOVA:OC5{MENOwG0v	Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
cord blood mononuclear cells	NV\FOoRNSW62aY\pdoFtKGG\|c3H5		NF7QcGE1QCCqcoO=	NEDqeGZCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIIP1ZpR6eGViQzDoZZJjd3KrbnegdJJwfGWjc3WgUFI{USxiTUS2TUwhVDh7VDDteZRidnRiZ3Xu[UBidmRicH;sfY1wenCqaYPtJIF1KE1\|NjDwc5NqfGmxbjDpcoZm[3SnZDDpckBpfW2jbjDjc5JlKGKub3;kJI1wdm:wdXPs[YFzKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SBuIFXDOVA:OC5{N{NOwG0v	Ml\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
cord blood mononuclear cells	MX3BcpRqfmm{YXygZZN{[Xl?		NY\NNWF6PDhiaILz	MVTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhSiCqYYLic5JqdmdicILveIVie2ViREOwUkwhVTR4STygRVcyXCCjbnSgWlc4USCvdYThcpQh\2WwZTDhcoQheG:ueX3vdpBpcXOvIHH0JG0{PiCyb4PpeIlwdiCxZjDwdo91\WG\|ZTDpcoZm[3SnZDDpckBpfW2jbjDjc5JlKGKub3;kJI1wdm:wdXPs[YFzKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHz1Z4ktKEWFNUC9NU4yOzoQvF2u	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNEGyN{c,OjB2MESxNlM9N2F-
cord blood mononuclear cells	MnLHRY51cX[rcnHsJIF{e2G7		NGLuWlQ1QCCqcoO=	M4HLdmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFic4XieJlx\SCEIHjhdoJwemmwZzDwdo91\WG\|ZTDEN\|BPNCCOM{PJMEBOPD[LLDDOPFhFKG23dHHueEBo\W6nIHHu[EBxd2y7bX;ydIhqe21iYYSgTVM3KHCxc3n0bY9vKGmwZnXjeIVlKGmwIHj1cYFvKGOxcnSgZoxwd2RibX;uc452[2ynYYKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdiCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeixiRVO1NF0yNjR4M988UU4>	NGLPdWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOFEzOyd-MkC0NFQyOjN:L3G+
cord blood mononuclear cells	MV;BcpRqfmm{YXygZZN{[Xl?		MnjtOFghcHK\|	NIDuZVVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIIP1ZpR6eGViQzDoZZJjd3KrbnegdJJwfGWjc3WgSFMxVixiRUO1S{whUTh3VjygUFkxVSCvdYThcpQh\2WwZTDhcoQheG:ueX3vdpBpcXOvIHH0JGk{PiCyb4PpeIlwdiCrbn\lZ5Rm\CCrbjDoeY1idiClb4LkJIJtd2:mIH3vco9vfWOuZXHyJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25iYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJuIFXDOVA:Oy52N{ROwG0v	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
TZM-bl	MnTQRY51cX[rcnHsJIF{e2G7		NGPMOIo1QCCqcoO=	Mnm3RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC\|dXL0fZBmKEJiaHHyZo9zcW6pIIDyc5Rm[XOnIIDvcJlud3KyaHnzcUBifCCPM{[gdI9{cXSrb36gbY5n\WO2ZXSgbY4hcHWvYX6gWHpONWKuIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNEGyN{c,OjB2MESxNlM9N2F-
TZM-bl	MXLBcpRqfmm{YXygZZN{[Xl?		M3\SN\|Q5KGi{cx?=	NGHwNWFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIIP1ZpR6eGViQ2LGNFJgSUdiaHHyZo9zcW6pIIDyc5Rm[XOnIIDvcJlud3KyaHnzcUBifCCLM{[gdI9{cXSrb36gbY5n\WO2ZXSgbY4hcHWvYX6gWHpONWKuIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	NVqwdZZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
TZM-bl	MVHBcpRqfmm{YXygZZN{[Xl?		M3qyNVQ5KGi{cx?=	M3PIVmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFic4XieJlx\SCEIHjhdoJwemmwZzDwdo91\WG\|ZTDwc4x6dW:{cHjpd40h[XRiSUO2JJBwe2m2aX;uJIlv\mWldHXkJIlvKGi3bXHuJHRbVS2kbDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl?	M{W5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEC0NVI{Lz5{MESwOFEzOzxxYU6=
MT4	M4XPUGFvfGm4aYLhcEBie3OjeR?=			M3\lUGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJdqdGRidInw[UBJUVZzIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wOFXPxE1w	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR\|OU[xNkc,OjB2M{m2NVI9N2F-
MT4	M17zPGFvfGm4aYLhcEBie3OjeR?=			MlnFRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCneIDy[ZN{cW6pIIDyc5Rm[XOnIFyxNGkwVDJ2ST;NOFZKN1Z6MlmvTVg1XiCvdYThcpQhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KHOnbHXjeIVlKGGodHXyJFUxKHCjc4Ph[4V{KG:oIFfSUE0zOTZiYomgUXRVKGG\|c3H5MEBGSzVyPUCuNVPPxE1w	MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2M{m2NVIoRjJyNEO5OlEzRC:jPh?=
MT4	NYPJbnFmSW62aY\pdoFtKGG\|c3H5	M3ixcVEhfU1?		M1jpOGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiZYjwdoV{e2mwZzDwdo91\WG\|ZTDMNVBHN012Nl2sTU9SPjGTIH31eIFvfCCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNic3Xs[YN1\WRiYYSgNUB2VSCxZjDHVmwuOzl4IHL5JG1VXCCjc4PhfUwhTUN3ME2wMlIz\|ryPLh?=	Mn60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2M{m2NVIoRjJyNEO5OlEzRC:jPh?=
MT4	Moe4RY51cX[rcnHsJIF{e2G7	M2D2[lEhfU1?		NU\Tc3hKSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDlfJBz\XO\|aX7nJJBzd3SnYYPlJGwyOEZxTUS2TU9VQTGVIH31eIFvfCCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNic3Xs[YN1\WRiYYSgNUB2VSCxZjDHVmwuOjR4IHL5JG1VXCCjc4PhfUwhTUN3ME2wMlI6\|ryPLh?=	NYfrcoZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0N\|k3OTJpPkKwOFM6PjF{PD;hQi=>
MT4	NHv6XIVCdnSrdnnyZYwh[XO\|YYm=	NYT3ToJUPSC3TR?=		MkTPRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCneIDy[ZN{cW6pIIDyc5Rm[XOnIFyxNGYwVTR4ST;JOVBXN0F5MW[vTVg1Xi:OOUDNJI12fGGwdDDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgd4Vt\WO2ZXSgZZQhPSC3TTDv[kBidXC{ZX7heolzKGK7IF3UWEBie3OjeTygSWM2OD1yLkROwG0v	MlizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2M{m2NVIoRjJyNEO5OlEzRC:jPh?=
MT4	M3TKNGFvfGm4aYLhcEBie3OjeR?=	MVi1JJVO		NFHDRnVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHX4dJJme3OrbnegdJJwfGWjc3WgUFExTi:PNE\JM2k2PFZxVkiyRUBufXSjboSgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJJNmdGWldHXkJIF1KDVidV2gc4YhVG:yaX7heolzKGK7IF3UWEBie3OjeTygSWM2OD1yLkOy{txONg>?	NWTTTohURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0N\|k3OTJpPkKwOFM6PjF{PD;hQi=>
MT4	NGPGZ4xCdnSrdnnyZYwh[XO\|YYm=	MmXsNUB2VQ>?		NVfCeYkySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDlfJBz\XO\|aX7nJJBzd3SnYYPlJGwyOEZxTUS2UE9KPTCYL1G3NXZufXSjboSgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJJNmdGWldHXkJIF1KDFidV2gc4YhT1KOLUK4OkBjgSCPVGSgZZN{[XluIFXDOVA:OC5\|N988UU4>	M2m4dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEO5OlEzLz5{MESzPVYyOjxxYU6=
MT4	NG\NeFdCdnSrdnnyZYwh[XO\|YYm=	M3PmU\|UhfU1?		MXTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGW6cILld5NqdmdicILveIVie2ViTEGwTU9IPDiYL1m1OHYwSTdzVj;JPFRXN0x7MF2gcZV1[W62IHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDz[Yxm[3SnZDDheEA2KHWPIH;mJJNieXWrbnH2bZIh[nliTWTUJIF{e2G7LDDFR\|UxRTBwNUJOwG0v	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR\|OU[xNkc,OjB2M{m2NVI9N2F-
BESM	MkGwRY51cXS{eYDhco9{d22jbDDhd5NigQ>?		NETnOlM5QCCqcoO=	NID6fFBCdnSrdIL5dIFvd3OxbXHsJIFkfGm4aYT5JIFo[Wmwc4SgWJJ6eGGwb4PvcYEh[3K3enmgZY1ie3SrZ3;0[ZMhcW6oZXP0[YQhcW5iQlXTUUBk\WyuczDt[YF{fXKnZDDh[pRmeiB6ODDodpMheG:\|dHnu[oVkfGmxbjDifUBJXFNiYYPzZZktKEWFNUC9NVLPxE1w	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV2N{ixPUc,OjB3NEe4NVk9N2F-
BESM	NIH4[Y9EgXSxdH;4bYNqfHliYYPzZZk>		NFj3U245QCCqcoO=	NXryPJZNS3m2b4TvfIlkcXS7IHHnZYlve3RiQlXTUUBk\WyuczDh[pRmeiB6ODDodpMh[nliSGTTJIF{e2G7LDDFR\|UxRTN{zszNMi=>	NVzuUo9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1OFc5OTlpPkKwOVQ4QDF7PD;hQi=>
CMEC/D3	NH\yOXNHfW6ldHnvckBie3OjeR?=		MVWzNEBucW6\|	MY\Jcohq[mm2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gR21GSy:GMzDj[YxteyC3c3nu[{BPSkRvQXLhJIF{KHO3YoP0doF1\SCjZoTldkA{OCCvaX7zJIJ6KG[ub4egZ5l1d22ndILpZ{BidmGueYPpd{whUUN3ME2xMlfPxE1w	Mmj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3MEW5NlgoRjNzNUC1PVI5RC:jPh?=
CMEC/D3	MnvWSpVv[3Srb36gZZN{[Xl?		NGK4XI8{OCCvaX7z	MYPJcohq[mm2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gR21GSy:GMzDj[YxteyC3c3nu[{Bk[WylZXnuMWFOKGG\|IIP1ZpN1emG2ZTDh[pRmeiB\|MDDtbY5{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0z\|ryPLh?=	NVuxXlVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1NFU6OjhpPkOxOVA2QTJ6PD;hQi=>
12D7-MDR	NHHqdopHfW6ldHnvckBie3OjeR?=		NXXj[Yx{OzBibXnudy=>	MXrJcohq[mm2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gNVJFPy2PRGKgZ4VtdHNidYPpcochVkKGLVHiZUBieyC\|dXLzeJJifGViYX\0[ZIhOzBibXnud{BjgSCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9OU45\|ryPLh?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTVyNUmyPEc,OzF3MEW5Nlg9N2F-
12D7-MDR	Ml;sSpVv[3Srb36gZZN{[Xl?		M4fUPVMxKG2rboO=	MXvJcohq[mm2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gNVJFPy2PRGKgZ4VtdHNidYPpcoch[2GuY3Xpck1CVSCjczDzeYJ{fHKjdHWgZYZ1\XJiM{CgcYlveyCkeTDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:QS5zzszNMi=>	M3fBRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUC1PVI5Lz5\|MUWwOVkzQDxxYU6=
12D7	MWHBcpRqfmm{YXygZZN{[Xl?		NIrVXFc{KGSjeYO=	M{Wx[mFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTFHJJIlv\mWldHXkJIlvKGi3bXHuJFEzTDdiY3XscJMhd3[ncnX4dJJme3OrbnegdE1oeCCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hWDJ2IHzleoVtKGG2IEG6NUBz[XSrbzDv[kB1\XO2IHPvcZBwfW6mIITvJIFj[WOjdnnyJIlv[3WkYYTl[EBnd3JiMzDkZZl{KG[xbHzve4VlKGK7IH\vcIxwf2WmIHL5JJJmeGyjY3Xt[Y51KG:oIH\y[ZNpKG2nZHn1cUBkd262YXnubY5oKGOxbYDveY5l	NFfJcJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUWwOVkzQCd-M{G1NFU6Ojh:L3G+
12D7	MXvBcpRqfmm{YXygZZN{[Xl?	NX\neId5OC5yODD0c{AyNjJ3IIXN	MX6zJIRigXN?	MVHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEyDSTDpcoZm[3SnZDDpckBpfW2jbjCxNmQ4KGOnbHzzJI93\XKneIDy[ZN{cW6pIICt[5Ah[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHAzPCCuZY\lcEBifCByLkC4JJRwKDFwMkWgeW0hcW6ldXLheIVlKG[xcjCzJIRigXNiZn;scI94\WRiYomgdoVxdGGlZX3lcpQhd2ZiZoLld4ghdWWmaYXtJINwdnSjaX7pcoch[2:vcH;1coQh[W6mIH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCHTFnTRS=>	NEiwUZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUWwOVkzQCd-M{G1NFU6Ojh:L3G+
SJ-GBM2	M3PVcJFJXFNiYYPzZZk>			NGXUbpByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	MkniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NIHs[pRyUFSVIHHzd4F6			MojMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M3nIb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	M1nQcZFJXFNiYYPzZZk>			NITye4dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NV\vZnFNeUiWUzDhd5NigQ>?			NYTKR2pUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MlrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	M{jDTJFJXFNiYYPzZZk>			NHi2T4tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MlnudWhVWyCjc4PhfS=>			M3ey[5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	NIrKRlVyUFSVIHHzd4F6			NV\TSpZOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MnK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MT2	NH;yZZJCdnSrdnnyZYwh[XO\|YYm=		M1TjPFUh\GG7cx?=	NHLwe4xCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDJiY3XscJMh[XO\|ZYPz[YQh[XNidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBi\nSncjC1JIRigXNiYomgXHRVKGG\|c3H5MEBGSzVyPUCuNFA1Qc7:TT6=	M4frbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU5PC9pPlPoSW1DVDxxYU6=
HepG2	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=		MmXmOUBl[Xm\|	NVzQVJl6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEWg[IF6eyCkeTDYWHQh[XO\|YYmsJGNEPTB;Nz60{txONg>?	M{DmdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU5PC9pPlPoSW1DVDxxYU6=
skeletal myoblast cells	M1v2NmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NH\ERYI4OiCqb4Xydy=>	M1nSdGRPTEl8IFP5eI91d3irY3n0fUBqdiCYaYTyc{whPzJiaH;1dkwhcW5icnH0JJNs\WyndHHsJI16d2KuYYP0JINmdGy\|LDDJR\|UxRTF{LkC1{txONg>?	NX;DPItoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTh2Lze+R4hGVUKOPD;hQi=>
MT2	MXTDfZRwfG:6aXPpeJkh[XO\|YYm=		M1\hRlUh\GG7cx?=	NEDtTVdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXDJiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDViZHH5d{BjgSC[VGSgZZN{[XluIFPDOVA:OTlwMd88UU4>	NILMOJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2QDRxJ{7DbGVOSkx:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Growth inhibition assay	Cell viability; PubMed: 22271897 Haematologica Histograms show the proliferation of RPMI, LP1, U266, OPM2 and MM1S cell lines treated with nelfinavir (1 μM to 10 μM).	22271897
Western blot	p-eIF2Aα / eIF2Aα / ATF4 / GRP78 / CHOP ; PubMed: 21697087 J Biol Chem U251 cells were mock-treated (0) or treated with Nelfinavir (NFV) (20 μm) for 4 or 24 h then whole cell lysates were immunoblotted for P-eIF2α, eIF2α, ATF4, GRP78, CHOP, and Ran, as indicated. SOD1 / SOD2 / catalase ; PubMed: 27280849 PLoS One Protein lysates derived from MDA-MB231, MCF-7, or breast epithelial cells, treated with 10 μM nelfinavir for the indicated time points, were immunoblotted with anti- SOD1, anti-SOD2 and anti-catalase. Beta-actin was used as loading control. PAX3 / MITF ; PubMed: 26977879 Cancer Cell Western blot of the indicated cell lines treated with 10 μM nelfinavir for 24 hr for PAX3, MITF, and ERK2.	21697087 27280849 26977879
Immunofluorescence	LC3 / p62 ; PubMed: 27330277 Drug Des Devel Ther Immunofluorescence of cells treated with control 0.1% dimethyl sulfoxide or 10 μM nelfinavir for 24 hours. Scale bars indicate 10 μm and apply to all images. Punctate LC3 were quantified as autophagosomes and punctate p62 were quantified as sequestosomes, P<0.01, *P<0.001. (C and D) Western blot of lysates prepared following 24 hours of drug treatment. Nelfinavir was used at 10 μM and the autophagy clearance inhibitor chloroquine at 10 μM. PAX3 / MITF ; PubMed: 26977879 Cancer Cell Immunofluorescence analysis for PAX3 and MITF in WM266-4 cells left untreated or treated with 10 μM nelfinavir for 24 hr; scale bars, 50 μm. p-SMAD2 ; PubMed: 26977879 Cancer Cell Immunofluorescence analysis for phospho-SMAD2 in melanoma cells treated with nelfinavir; scale bars, 10 μm	27330277 26977879

In vivo

In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. Initial investigation of the compound in fed rats indicated an oral bioavailability of 43%. In contrast, the oral bioavailability was significantly reduced in fasted rats to 29%. Nelfinavir demonstrated significant oral bioavailabilability across a range of species including dogs (47%), marmosets (17%), and cynomolgus monkeys (26%). It has a long plasma half-life after oral dosing that is likely due to a combination of slow dissolution and absorption. nelfinavir is well absorbed in humans particularly when administered with food and possesses minimal and easily managed side effects^[1].

Protocol

Animal Research: ^[1]	- Collapse Animal Models: Sprague-Dawley rats Dosages: 12.5 to 25 mg/kg (i.v); 25 to 50 mg/kg (oral) Administration: i.v and oral administration (Only for Reference)

References

[1] Kaldor SW, et al.J Med Chem, 1997,40(24):3979-85.

Solubility (25°C)

In vitro	DMSO	100 mg/mL (150.62 mM)
	Water	Insoluble
	Ethanol	'100 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Nelfinavir Mesylate SDF

Molecular Weight	663.89
Formula	C₃₃H₄₉N₃O₇S₂
CAS No.	159989-65-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Viracept, AG1343
Smiles	CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HIV Protease Signaling Pathway Map

Related HIV Protease Products

Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.
Marimastat (BB-2516) ^New

Marimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
Ledipasvir (GS5885) ^New

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Ritonavir

Ritonavir (ABT-538, A 84538, RTV, Norvir, Norvir Softgel) is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. Ritonavir induces apoptosis.
Lopinavir

Lopinavir (ABT-378) is a potent HIV protease inhibitor with K_i of 1.3 pM in a cell-free assay.
Darunavir Ethanolate

Darunavir Ethanolate (TMC-114, UIC 94017) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
Amprenavir

Amprenavir (141W94, VX-478, KVX-478) is a potent PXR-selective agonist, and an HIV protease inhibitor, used to treat HIV.
Limonin

Limonin is a triterpenoid enriched in citrus fruits, which has antivirus and antitumor ability.
Atazanavir Sulfate

Atazanavir Sulfate (BMS-232632) is a HIV protease inhibitor with K_i of 2.66 nM in a cell-free assay.

Features:Atazanavir is generally more potent than other HIV-1 Prt inhibitors, including IDV, SQV, RTV, NFV, and APV.
MG-132

MG132 (Z-Leu-Leu-Leu-al) is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Nelfinavir Mesylate